A preventive-services task force omitted three key issues in recommending against PSA screening: the impossibility of addressing the probabilities and uncertainties coherently during routine visits, variable management of PSA levels, and a lack of cost-effectiveness.
No takes yet. Share an insight, caveat, or question.
Brett et al. (2011) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: